Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention
- PMID: 11012188
- DOI: 10.1002/stem.5530160719
Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention
Abstract
The factor which is the primary regulator of megakaryocyte and platelet production has recently been identified as the ligand for the receptor Mpl. This discovery has resulted in substantial advances in our understanding of platelet homeostasis. The access to new experimental reagents has enabled studies of the endogenous circulating form of this ligand, endogenous thrombopoietin, in normal individuals and in patients with altered platelet numbers. The relationship of endogenous TPO in health and disease will be examined with consideration of the implications for successful therapeutic intervention with exogenous recombinant Mpl ligands in selected settings.
Similar articles
-
Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.Semin Hematol. 2007 Oct;44(4 Suppl 5):S35-45. doi: 10.1053/j.seminhematol.2007.11.005. Semin Hematol. 2007. PMID: 18096471 Review.
-
Megakaryocyte development and platelet production.Br J Haematol. 2006 Sep;134(5):453-66. doi: 10.1111/j.1365-2141.2006.06215.x. Br J Haematol. 2006. PMID: 16856888 Review.
-
Thrombopoietin and myelodysplastic syndromes.Int J Hematol. 2000 Aug;72(2):173-7. Int J Hematol. 2000. PMID: 11039665 Review.
-
Thrombopoietin gene transfer-mediated enhancement of angiogenic responses to acute ischemia.Circ Res. 2005 Aug 19;97(4):337-45. doi: 10.1161/01.RES.0000179534.17668.f8. Epub 2005 Jul 28. Circ Res. 2005. PMID: 16051888
-
The Mpl receptor expressed on endothelial cells does not contribute significantly to the regulation of circulating thrombopoietin levels.Exp Hematol. 2006 Jan;34(1):82-6. doi: 10.1016/j.exphem.2005.09.008. Exp Hematol. 2006. PMID: 16413394
Cited by
-
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia.Ther Adv Hematol. 2019 May 9;10:2040620719837906. doi: 10.1177/2040620719837906. eCollection 2019. Ther Adv Hematol. 2019. PMID: 31156798 Free PMC article. Review.
-
Eltrombopag-based combination treatment for immune thrombocytopenia.Ther Adv Hematol. 2018 Oct 4;9(10):309-317. doi: 10.1177/2040620718798798. eCollection 2018 Oct. Ther Adv Hematol. 2018. PMID: 30344993 Free PMC article. Review.
-
A Review of Romiplostim Mechanism of Action and Clinical Applicability.Drug Des Devel Ther. 2021 May 26;15:2243-2268. doi: 10.2147/DDDT.S299591. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34079225 Free PMC article. Review.
-
Immune thrombocytopenia.Hematol Oncol Clin North Am. 2013 Jun;27(3):495-520. doi: 10.1016/j.hoc.2013.03.001. Hematol Oncol Clin North Am. 2013. PMID: 23714309 Free PMC article. Review.
-
Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia.Front Pediatr. 2015 Aug 13;3:70. doi: 10.3389/fped.2015.00070. eCollection 2015. Front Pediatr. 2015. PMID: 26322297 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources